Search

Search Constraints

You searched for: Author/Creator Dall'Olio, Filippo G.

Search Results

1. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non–small cell lung cancer treated with first-line pembrolizumab. (June 2021)

2. CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors. (October 2020)

3. Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience. (November 2020)

4. ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data. (July 2020)

5. Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC. (February 2022)

6. Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC. (November 2021)